Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte
H Tilly, N Mounier, P Lederlin, et al.
Blood
|
June 14, 2000
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA)
N Mounier, C Haioun, B F Cole, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 2, 2009
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma
C Haioun, N Mounier, J F Emile, et al.
Leukemia
|
March 31, 1998
Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte
P Brice, D Cazals, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2008
Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions
C M Raynaud, S J Jang, P Nuciforo, et al.
The American Journal of Surgical Pathology
|
February 27, 2001
Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study
D Cazals-Hatem, M André, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2007
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
P Morel, P Gaulard, C Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2004
Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte
N Mounier, C Gisselbrecht, J Brière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2004
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
N Mounier, C Gisselbrecht, J Brière, et al.
Blood Cancer Journal
|
November 5, 2013
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
T Cluzeau, C Moreilhon, N Mounier, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte
H Tilly, N Mounier, P Lederlin, et al.
Blood
|
June 14, 2000
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA)
N Mounier, C Haioun, B F Cole, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 2, 2009
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma
C Haioun, N Mounier, J F Emile, et al.
Leukemia
|
March 31, 1998
Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte
P Brice, D Cazals, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2008
Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions
C M Raynaud, S J Jang, P Nuciforo, et al.
The American Journal of Surgical Pathology
|
February 27, 2001
Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study
D Cazals-Hatem, M André, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2007
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
P Morel, P Gaulard, C Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2004
Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte
N Mounier, C Gisselbrecht, J Brière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2004
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
N Mounier, C Gisselbrecht, J Brière, et al.
Blood Cancer Journal
|
November 5, 2013
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
T Cluzeau, C Moreilhon, N Mounier, et al.
Page
of 7